MilliporeSigma Introduces MILLIPLEX® High Sensitivity Panel for Faster, More Economical Cytokine Assays
- Product offers smaller sample volumes and four times higher throughput than traditional assays
Billerica, Massachusetts, December 2, 2016 — MilliporeSigma today launched the MILLIPLEX® MAP Human High Sensitivity cytokine panel for faster and more cost-effective human cytokine assays. The new panel allows researchers to achieve four times higher throughput than traditional assays while using smaller sample sizes.
The new assay is the first 384-well kit for use with the Luminex FLEXMAP 3D® platform. Researchers can now simultaneously measure multiple protein biomarkers in a single sample, collecting up to 366 data points per plate in the same time it would take to run a 96-well plate. The new kit delivers high specificity and sensitivity and requires less than 10 μm of sample.
“The availability of validated 384-well kits is an important new tool for customers with limited sample volumes who require high throughput, specificity and selectivity,” said Jason Apter, Head of Research Solutions Strategic Marketing & Innovation, MilliporeSigma. “Simply put, researchers with limited sample volumes will get more results, faster.”
Rush Medical College’s laboratory has been using customized designed 384-well assays on the Luminex FLEXMAP 3D® system for nearly two years.
“Now that MilliporeSigma is offering off-the-shelf assay kits, we expect to run even more assays in this format, which will help expedite our research,” said Jeffery Borgia, Assistant Professor, Rush Medical College.
Assays help researchers identify and quantify soluble proteins and peptides that play an important role in the immune system and its response to antigens, as well as disease states such as inflammatory disease, allergic reactions, irritable bowel disease, sepsis and cancer.
The new MILLIPLEX® MAP Human High Sensitivity cytokine panels expand MilliporeSigma’s existing portfolio of immunoassays for human cytokines, essential tools for academic centers, contract research organizations and biotech/pharma companies.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck KGaA, Darmstadt, Germany, generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the „Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Based on high demand expected to continue throughout the year and a very strong first quarter of 2021 with net sales of EUR 4.63 bn resulting in EBITDA pre of EUR 1.51 bn and EPS pre of EUR 2.18, ...